Researchers at Rockefeller University have developed a groundbreaking approach to enhance immune responses by genetically engineering hematopoietic stem and progenitor cells (HSPCs) to produce broadly neutralizing antibodies (bNAbs) against pathogens such as HIV, malaria, and influenza. This innovative method leverages a small number of edited B cells, enabling them to act as lifelong protein factories, continuously producing essential antibodies and potentially other therapeutic proteins throughout the body.

The significance of this study lies in its ability to address the limitations of traditional vaccination strategies, which often require frequent updates due to rapid pathogen mutation. By focusing on HSPCs, the researchers achieved long-lasting immunity in mouse models, with engineered B cells producing high levels of bNAbs even from a minimal number of edited cells. Notably, a single booster shot was sufficient to amplify antibody levels over an extended period, demonstrating the potential for durable protection against rapidly evolving diseases.

This advancement could shift current paradigms in vaccine development and protein therapy, offering a platform for creating tailored therapeutic proteins in vivo. The ability to produce various proteins, such as enzymes or antibodies for treating metabolic diseases and cancers, opens new avenues for personalized medicine. As the research progresses toward human applications, the higher editing efficiency observed in human HSPCs suggests a promising translational pathway for developing lifelong treatments that could significantly enhance healthspan and combat age-related diseases.

Source: lifespan.io